Searching for a role of procalcitonin determination in COVID-19 : a study on a selected cohort of hospitalized patients
Articolo
Data di Pubblicazione:
2021
Citazione:
Searching for a role of procalcitonin determination in COVID-19 : a study on a selected cohort of hospitalized patients / A. Dolci, C. Robbiano, E. Aloisio, M. Chibireva, L. Serafini, F. Stefania Falvella, S. Pasqualetti, M. Panteghini. - In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. - ISSN 1434-6621. - 59:2(2021 Feb), pp. 433-440. [https://doi.org/10.1515/cclm-2020-1361]
Abstract:
Objectives: Procalcitonin (PCT) has been proposed for differentiating viral vs. bacterial infections. In COVID-19, some preliminary results have shown that PCT testing could act as a predictor of bacterial co-infection and be a useful marker for assessment of disease severity.
Methods: We studied 83 COVID-19 hospitalized patients in whom PCT was specifically ordered by attending physicians. PCT results were evaluated according to the ability to accurately predict bacterial co-infections and death in comparison with other known biomarkers of infection and with major laboratory predictors of COVID-19 severity.
Results: Thirty-three (39.8%) patients suffered an inhospital bacterial co-infection and 44 (53.0%) patients died. In predicting bacterial co-infection, PCT showed a relatively low accuracy (area under receiver-operating characteristic [ROC] curve [AUC]: 0.757; 95% confidence
interval [CI]: 0.651–0.845), with a strength for detecting the outcome not significantly different from that of white blood cell count and C-reactive protein (CRP). In predicting patient death, PCT showed an AUC of 0.815 (CI: 0.714–0.892), not better than those of other more common laboratory tests, such as blood lymphocyte percentage (AUC: 0.874, p=0.19), serum lactate dehydrogenase (AUC: 0.860,
p=0.47), blood neutrophil count (AUC: 0.845, p=0.59), and serum albumin (AUC: 0.839, p=0.73).
Conclusions: Procalcitonin (PCT) testing, even when appropriately ordered, did not provide a significant added value in COVID-19 patients when compared with more consolidated biomarkers of infection and poor clinical outcome. The major application of PCT in COVID-19 is its
ability, associated with a negative predictive value >90%, to exclude a bacterial co-infection when a rule-out cut-off (<0.25 μg/L) is applied.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
bacterial infection; COVID-19; procalcitonin; severe acute respiratory syndrome coronavirus 2
Elenco autori:
A. Dolci, C. Robbiano, E. Aloisio, M. Chibireva, L. Serafini, F. Stefania Falvella, S. Pasqualetti, M. Panteghini
Link alla scheda completa: